Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Halozyme (HALO) and Elevance Health (ELV)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF – Research Report), Halozyme (HALO – Research Report) and Elevance Health (ELV – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Roche Holding AG (RHHVF)
Bernstein analyst Justin Smith maintained a Buy rating on Roche Holding AG today and set a price target of CHF400.00. The company’s shares closed last Wednesday at $424.00.
Smith has an average return of
According to TipRanks.com, Smith is ranked #2012 out of 12040 analysts.
Currently, the analyst consensus on Roche Holding AG is a Moderate Buy with an average price target of $439.28, which is a -1.6% downside from current levels. In a report issued on January 15, TipRanks – Anthropic also initiated coverage with a Buy rating on the stock with a CHF385.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Halozyme (HALO)
Morgan Stanley analyst Sean Laaman maintained a Buy rating on Halozyme today and set a price target of $78.00. The company’s shares closed last Wednesday at $72.83.
According to TipRanks.com, Laaman is a 5-star analyst with an average return of
Currently, the analyst consensus on Halozyme is a Moderate Buy with an average price target of $81.20, a 14.4% upside from current levels. In a report issued on January 15, TipRanks – xAI also upgraded the stock to Buy with a $80.00 price target.
Elevance Health (ELV)
Morgan Stanley analyst Erin Wright maintained a Hold rating on Elevance Health today and set a price target of $352.00. The company’s shares closed last Wednesday at $341.85.
According to TipRanks.com, Wright is a 5-star analyst with an average return of
Currently, the analyst consensus on Elevance Health is a Strong Buy with an average price target of $394.73, implying a 25.1% upside from current levels. In a report released yesterday, TipRanks – OpenAI also downgraded the stock to Hold with a $349.00 price target.
